Adiso Therapeutics

Artugen is currently enrolling in C. difficile infection study.

SHARE
Aug. 25, 2021

Artugen is currently enrolling subjects in “A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a C. difficileinfection”

We are looking for volunteers to participate in a new study to help lower the recurrence rate of C. difficile infections. If you are someone who was diagnosed, treated, and recovered from the infection and are now healthy, you are eligible to enroll.